“Bimekizumab Long-Term Efficacy in Patients With Moderate to Severe Plaque Psoriasis After Switching From Adalimumab, Ustekinumab, or Secukinumab: Results from Up to 4 Years of Total Treatment from BE BRIGHT and BE RADIANT”. SKIN The Journal of Cutaneous Medicine 8, no. 6 (November 18, 2024): s433. Accessed November 7, 2025. https://skin.dermsquared.com/skin/article/view/3092.